Inspira Technologies Appoints Former Johnson & Johnson Executive and Investment Firm Director to Board.

Inspira Technologies has appointed Mike Hershkovitz as VP of Global Sales and Sivan Matza as a board member. Hershkovitz brings 20 years of experience in healthcare sales and commercial management, including a senior role at Johnson & Johnson. Matza is a director at a leading international investment management firm with experience in global finance, regulation, and accounting. Both appointments are expected to enhance Inspira's commercialization and governance as the company expands globally.

Inspira Technologies (NASDAQ: IINN) has announced two significant leadership appointments to bolster its global commercialization and governance efforts. Mike Hershkovitz has been appointed as Vice President of Global Sales, while Sivan Matza has joined the board of directors as an independent member Inspira Appoints Former Johnson & Johnson Executive as VP of Global Sales and New Board Member from a Leading International Investment Firm^[1].

Mike Hershkovitz brings nearly two decades of leadership in U.S. and international healthcare markets, including senior commercial roles at Johnson & Johnson. His appointment as Vice President of Global Sales is expected to drive Inspira's sales strategy and hospital adoption initiatives worldwide Inspira Appoints Former Johnson & Johnson Executive as VP of Global Sales and New Board Member from a Leading International Investment Firm^[1].

Sivan Matza, a director at a leading international investment management firm overseeing tens of billions of dollars in assets, will serve as an independent member of the board of directors. She will also join the compensation, audit, and financial statement examination committees. Her extensive experience in global finance, regulation, and accounting strengthens Inspira’s governance framework as the company accelerates its commercial expansion Inspira Appoints Former Johnson & Johnson Executive as VP of Global Sales and New Board Member from a Leading International Investment Firm^[1].

These appointments follow Inspira's recent FDA clearance for its INSPIRA™ ART100 system, which is approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S. The company is also advancing the HYLA™ blood sensor platform for continuous, non-invasive monitoring Inspira Appoints Former Johnson & Johnson Executive as VP of Global Sales and New Board Member from a Leading International Investment Firm^[1].

In parallel, Citius Oncology (Nasdaq: CTOR) has signed an exclusive commercialization agreement with EVERSANA to support the planned U.S. launch of LYMPHIR™ in Q4 2025. EVERSANA will provide a suite of pre- and post-launch services, including medical information, pharmacovigilance, revenue cycle management, program management, data and analytics, and channel management Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™^[2].

These strategic moves underscore the industry's focus on consolidation, cross-sector collaboration, and potential strategic partnerships, reflecting broader trends in the life-support and MedTech landscape Inspira Appoints Former Johnson & Johnson Executive as VP of Global Sales and New Board Member from a Leading International Investment Firm^[1].